Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Pentoxifylline in the treatment of LUTS/BPH: A preliminary study

Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Pentoxifylline in the treatment of LUTS/BPH in two 30 persons groups of patients: A preliminary study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210729052012N1

Enrollment

Registered

2022-01-20

Start date

2022-02-04

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostate Hyperplasia. Enlarged prostate with lower urinary tract symptoms

Interventions

Intervention 1: Intervention group: Tamsulosin 0.4mg everyday and Pentoxyfilline 400mg every 8 hour in 12 weeks were given. Intervention 2: Control group: Tamsulosin 0.4mg everyday and placebo eve

Eligibility

Sex/Gender

Male

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: Age>40 International Prostate Symptom Score(IPSS)>13 Prostate Volume>20ml maximum urinary flow rate(Qmax)100ml creatinine(Cr)<2

Exclusion criteria

Exclusion criteria: Age 250 mL exposure to sex hormone within 3 months prior history of severe liver impairment history of severe cardiovascular diseases severe hypotension history of neurogenic bladder history of urethral stricture

Design outcomes

Primary

Measure	Time frame
International Prostate Symptom Score. Timepoint: At the beginning of the study and 12 weeks after treatment. Method of measurement: International Prostate Symptom Score chart.;Quality of Life. Timepoint: At the beginning of the study and 12 weeks after treatment. Method of measurement: Quality of life due to urinary symptoms chart.;Maximum urinary flow rate. Timepoint: At the beginning of the study and 12 weeks after treatment. Method of measurement: Uroflowmetry.;Voided volume. Timepoint: At the beginning of the study and 12 weeks after treatment. Method of measurement: Uroflowmetry.	—

Measure

Time frame

International Prostate Symptom Score. Timepoint: At the beginning of the study and 12 weeks after treatment. Method of measurement: International Prostate Symptom Score chart.;Quality of Life. Timepoint: At the beginning of the study and 12 weeks after treatment. Method of measurement: Quality of life due to urinary symptoms chart.;Maximum urinary flow rate. Timepoint: At the beginning of the study and 12 weeks after treatment. Method of measurement: Uroflowmetry.;Voided volume. Timepoint: At the beginning of the study and 12 weeks after treatment. Method of measurement: Uroflowmetry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Dehghanmanshadi

Shiraz University of Medical Sciences

alireza.dehghan68@gmail.com+98 71 3820 6907

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026